A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Completed
Daiichi Sankyo Inc.
Phase 1
2007-01-01
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and
best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3
status.
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Completed
Daiichi Sankyo, Inc.
Phase 1
2007-01-01
Patients received oral AC220 daily for 14 days to study the side effects, tolerability and
best dose for treating relapsed or refractory acute myeloid leukemia, regardless of FLT3
status.
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Completed
Ambit Biosciences Corporation
Phase 1
2011-10-01
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when
combined with induction and consolidation therapy and as maintenance therapy following
induction and consolidation.
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Completed
Daiichi Sankyo Inc.
Phase 1
2011-10-01
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when
combined with induction and consolidation therapy and as maintenance therapy following
induction and consolidation.
A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)
Completed
Daiichi Sankyo, Inc.
Phase 1
2011-10-01
The purpose of this study is to define the maximum tolerated dose (MTD) of AC220 when
combined with induction and consolidation therapy and as maintenance therapy following
induction and consolidation.
AC220 for Children With Relapsed/Refractory ALL or AML
Completed
Ambit Biosciences Corporation
Phase 1
2011-09-01
This is a phase I study of the investigational drug AC220 combined with cytarabine and
etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute
myelogenous leukemia (AML).
AC220 for Children With Relapsed/Refractory ALL or AML
Completed
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1
2011-09-01
This is a phase I study of the investigational drug AC220 combined with cytarabine and
etoposide in pediatric patients with relapsed acute lymphoblastic leukemia (ALL) and acute
myelogenous leukemia (AML).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
